Your shopping cart is currently empty

Cbl-b-IN-30 is an orally active inhibitor of Casitas B-lineage lymphoma-b (CBLB). It specifically binds to CBLB and inhibits its E3 ubiquitin ligase activity, with an IC50 value of 9.1 nM. Cbl-b-IN-30 promotes IL-2 secretion (EC50 value of 187.5 nM) and enhances T cell activation. This compound also exhibits antitumor activity and can induce immune memory. It is useful for colon cancer research.
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | Cbl-b-IN-30 is an orally active inhibitor of Casitas B-lineage lymphoma-b (CBLB). It specifically binds to CBLB and inhibits its E3 ubiquitin ligase activity, with an IC50 value of 9.1 nM. Cbl-b-IN-30 promotes IL-2 secretion (EC50 value of 187.5 nM) and enhances T cell activation. This compound also exhibits antitumor activity and can induce immune memory. It is useful for colon cancer research. |
| In vitro | Cbl-b-IN-30 (Compound 10) enhances IL-2 secretion and T cell activation in human T cells activated by anti-CD3 antibody. It specifically binds to CBLB and inhibits its E3 ubiquitin ligase activity, with an IC50 value of 9.1 nM. Cbl-b-IN-30 shows no significant inhibition of CYP1A2/2C9/2C19/2D6/3A4 (IC50 >50 μM), has an IC50 >30 μM for hERG, and exhibits low risk for drug interactions and cardiac safety issues. |
| In vivo | Cbl-b-IN-30 (Compound 10) administered orally at doses of 3-30 mg/kg once daily for 15 days, inhibits tumor growth in BALB/c mice with syngeneic CT26 tumors. When used at 30 mg/kg orally once a day for 15 days in combination with anti-PD-1 antibody treatment, it induces lasting immune memory in BALB/c mice, as evidenced by no tumor growth and 100% survival upon rechallenge with CT26 cells. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.